Infection Due to Fluconazole-Resistant Candida in Patients with AIDS: Prevalence and Microbiology
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A cross-sectional study was conducted to assess the prevalence and microbiology of oral infection due to fluconazole-resistant Candida in patients with AIDS. Oral swab specimens for fungal cultures were obtained from 100 consecutive outpatients with CD4 lymphocyte counts of < 200/mm3. At least one fungal organism demonstrating in vitro resistance to fluconazole (minimum inhibitory concentration, > or = 8 micrograms/mL) was isolated from 26 (41%) of 64 patients for whom cultures were positive. When fluconazole-resistant C. albicans was isolated, in vitro resistance correlated with clinical thrush. None of 10 patients from whom only non-albicans species of Candida were isolated had active thrush. The patients from whom fluconazole-resistant Candida albicans was isolated had lower CD4 cell counts (median, 9/mm3), a greater number of treated episodes of thrush (median, 4.5), and a greater median duration of prior fluconazole treatment (231 days) than did patients from whom fluconazole-susceptible C. albicans was isolated (median CD4 cell count, 58/mm3 [P = .004]; median number of treated episodes of thrush, 2.0 [P = .001]; and median duration of prior fluconazole treatment, 10 days [P = .01]; respectively). In a multivariate analysis, the number of episodes and duration of fluconazole therapy were independent predictors of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322 · cited 1×
“With the increasing use of oral azoles as prophylaxis for and treatment of mucosal candidiasis and invasive fungal infections, infection due to azole-resistant Candida is becoming recognized as a growing problem [2-11] .”
BackgroundPowderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321102 · Cited by 318 · cited 2×
“While fluconazole resistance has been associated with advanced immunosuppression and prolonged exposure to azoles [4, 11, 12], fluconazole therapy has been shown to reduce the frequency of cryptococcosis, esophageal candidiasis, and superficial fungal infections [13, 14].”
Background
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
“Recent reports suggest that in this clinical setting, approximately 30% of patients with advanced AIDS will develop azole-resistant Candida infection (152, 211).”
BackgroundSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Loeffler, J., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/344658 · Cited by 228
“was found in up to 46% of these patients [4, 5].”
BackgroundImmunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection
de Repentigny, L., Lewandowski, D., & Jolicoeur, P. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.729-759.2004 · Cited by 228
“glabrata increases after treatment with fluconazole (402) it is rarely if ever isolated as the sole cause of recurrent OPC (159, 273, 380, 445).”
BackgroundCurrent treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
White, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1998) · Clinical Infectious Diseases · doi:10.1086/515006 · Cited by 103
Talibi, D., & Raymond, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.1.231-240.1999 · Cited by 101
“However, the successful treatment of candidosis by FCZ has been impaired by the emergence of drug-resistant strains in patients undergoing long-term or prophylactic treatment, mostly AIDS patients (24, 39, 49).”
BackgroundVazquez, J. A., & Sobel, J. D. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00042-9 · Cited by 104
Prophylaxis with Weekly Versus Daily Fluconazole for Fungal Infections in Patients with AIDS
Havlir, D. V., Dubé, M. P., McCutchan, J. A., Forthal, D. N., Kemper, C. A., Dunne, M. W., Parenti, D. M., Kumar, P. N., White, A. C., Witt, M. D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/515018 · Cited by 72
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00137-5 · Cited by 67
Vazquez, J. A., Sobel, J. D., Peng, G., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. I. A. (1999) · Clinical Infectious Diseases · doi:10.1086/514746 · Cited by 51
“that assessed the microbiology of oral infection in AIDS patients, there was a trend toward the recovery of non-albicans Candida species alone or in combination with other Candida species when CHROMagar Candida medium (CHROMager Microbiology, Paris) was utilized rather than the standard Sabouraud dextrose agar medium…”
BackgroundMethodMasiá Canuto, M., Gutiérrez Rodero, F., Ortiz de la Tabla Ducasse, V., Hernández Aguado, I., Martín González, C., Sánchez Sevillano, A., & Martín Hidalgo, A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000323 · Cited by 46
Azole Resistance of Candida glabrata in a Case of Recurrent Fungemia
Posteraro, B., Tumbarello, M., La Sorda, M., Spanu, T., Trecarichi, E. M., De Bernardis, F., Scoppettuolo, G., Sanguinetti, M., & Fadda, G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00526-06 · Cited by 30
“glabrata resistance to azoles have previously been described and occur mainly in AIDS patients with oropharyngeal candidiasis (2, 4, 6, 11).”
Background
Metadata
- Authors
- Maenza, J. R., Merz, W. G., Romagnoli, M. J., Keruly, J. C., Moore, R. D., & Gallant, J. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-01-01
- Volume
- 24
- Issue
- 1
- Pages
- 28-34
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2096802435
- Cited by
- 141
- References
- 2
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.